Members of the Gainesville medical community said they are encouraged by the accelerated approval recently granted by the U.S. Food and Drug Administration to Lecanemab, an Alzheimer’s disease treatment sold under the brand name Leqembi. The decision creates a pathway that allows for provisional approval of drugs that treat serious illnesses for which other treatments are not available or functional.

Read More »